Article Details
Retrieved on: 2018-01-08 01:37:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>After being founded in March 2017, Juvenescence closed its first deal in July 2017, when it invested in <b>Insilico Medicine</b> (“Insilico”), a leader in applying artificial intelligence techniques to the challenges of drug discovery and development. Insilico's AI engine can generate novel compounds with ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here